US20010012837A1 - Anti-ulcer composition - Google Patents

Anti-ulcer composition Download PDF

Info

Publication number
US20010012837A1
US20010012837A1 US09/764,347 US76434701A US2001012837A1 US 20010012837 A1 US20010012837 A1 US 20010012837A1 US 76434701 A US76434701 A US 76434701A US 2001012837 A1 US2001012837 A1 US 2001012837A1
Authority
US
United States
Prior art keywords
composition
cationic component
percent
content
synthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/764,347
Other languages
English (en)
Inventor
Ivan Santar
Frantisek Kiss
Jiri Briestensky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpenstock Holdings Ltd
Original Assignee
Alpenstock Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpenstock Holdings Ltd filed Critical Alpenstock Holdings Ltd
Assigned to ALPENSTOCK HOLDINGS LIMITED reassignment ALPENSTOCK HOLDINGS LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRIESTENSKY, JIRI, KISS, FRANTISEK, SANTAR, IVAN
Publication of US20010012837A1 publication Critical patent/US20010012837A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/731—Cellulose; Quaternized cellulose derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/737—Galactomannans, e.g. guar; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8158—Homopolymers or copolymers of amides or imides, e.g. (meth) acrylamide; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/54—Polymers characterized by specific structures/properties
    • A61K2800/542—Polymers characterized by specific structures/properties characterized by the charge
    • A61K2800/5424—Polymers characterized by specific structures/properties characterized by the charge anionic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/54—Polymers characterized by specific structures/properties
    • A61K2800/542—Polymers characterized by specific structures/properties characterized by the charge
    • A61K2800/5426—Polymers characterized by specific structures/properties characterized by the charge cationic

Definitions

  • Peptic ulcer disease is a broad classification for more specific conditions known as gastric or duodenal ulcers. Ulcers are clinically characterized as an erosion of the mucosal lining of the gastrointestinal tract. Duodenal ulcers are four times more common than gastric ulcers in the general population; however, among NSAID users, gastric ulcers are more common.
  • PUD The etiology of PUD was originally thought to be an imbalance of several factors that included gastrointestinal secretions (gastric acid, pepsin, bile salts, and enzymes), and dietary intake (spicy foods, alcohol, caffeine). Later, it was discovered that Helicobacter pylori is present in more than 90% of duodenal ulcers and more than 75% of gastric ulcers not caused by NSAID use. PUD is therefore now treated as an infectious condition, cured with antibiotics. In the small percentage of PUD cases not caused by H. pylori, the cause can include the use of ulcerogenic drugs, mostly non-steroidal andinflammatory drugs (NSAIDs) and hypersecretory diseases.
  • NSAIDs non-steroidal andinflammatory drugs
  • Ulcers can be asymptomatic for an indefinite period of time. The most common symptom is pain. Weight loss and anorexia can occur in severe cases, and other non-specific symptoms include nausea, belching, bloating, abdominal distension, food intolerance, and heartburn. Complications of PUD could manifest as frequent symptoms, perforation, hemorrhage, and gastric outlet obstruction. Hemorrhage is the most common complication, occurring in an estimated 25% of cases, and sometimes is the initial presentation.
  • Antacids provide symptomatic relief by neutralizing acid in the stomach, but their duration of action requires the patient to take multiple doses each day. Side effects are diarrhoea (mainly caused by magnesium salts), constipation (associated with aluminum salts), mineral imbalance, and alkalosis. Compliance is often a problem with this regimen.
  • Histamine-2 receptor antagonists with cimetidine as the prototype, were introduced in late 70's, and ranitidine, famotidine, and nizatidine soon followed, and quickly became the most widely prescribed medications. They are highly effective in healing ulcers, however, recurrence was common, which led to the practice of maintenance therapy. These agents' most notable adverse effects are drug interactions of the cytochrome P450 system (most common with cimetidine).
  • misoprostol the first synthetic prostaglandin E 1 analog for the treatment of ulcers. It is a first-line therapy for active and preventive therapy of NSAID-induced gastric ulcers. This agent is also recommended for patients who cannot or should not discontinue NSAID therapy. Diarrhoea is the most common side effect and appears to be dose-dependent. However, misoprostol is a potential abortifacient, and its use is contraindicated in women who are pregnant or trying to conceive.
  • H. pylori PUD caused by H. pylori additionally requires antimicrobial therapy, but monotherapy is not recomrnended due to the potential for resistance. Antibiotic therapy should always be combined with acid-suppressive therapy when treating H. pylori.
  • the most common regimen for H. pylori eradication is triple antibiotics (amoxicillin or tetracycline/clarithromycin, metronidazole, and bismuth subsalicylate). Compliance with triple therapy plus an antisecretory drug (known as quadruple therapy) is difficult because of the number of pills the patient must take. Therefore many dual therapy regimens have been developed and are excellent alternatives. Side effects are based on the chosen antimicrobial agents and may include nausea, taste disturbance, diarrhoea, cramps and headache.
  • acid-suppressive therapy is omnipresent in PUD treatment and may involve various adverse effects as well as increase the treatment expenses for the patient.
  • the invention in particular involves the use of polyanhydroglucuronic acids and salts thereof.
  • polyanhydroglucuronic acid and salts there of as used herein also includes copolymers thereof, especially with anhydroglucose. This is hereinafter referred to as PAGA.
  • Co-pending patent application PCT IE98/00004 describes particular polyanhydroglucuronic acids and salts thereof and a method of preparing such compounds.
  • polyanhydroglucuronic acids and salts thereof includes the acids and salts referred to in this co-pending application.
  • this type of polymer has the advantage of being able to fulfil multiple functions in the gastrointestinal tract. Due to the bound cation(s) it can neutralise the excess acidity of the gastric acids. As an efficient haemostat it can assist in the control of eventual haemorraging complications. It can further carry active substances such as histamine-2 antagonists suppressing production of gastric acids or proton pump inhibitors.
  • a pharmaceutical composition for the prophylaxis or treatment of peptic ulcers including a biocompatible anionic polysaccharide material containing glucuronic acid.
  • the polysaccharide is derived from a starch, cellulose or gum, or is of microbial origin.
  • the polysaccharide material is polyanhydroglucuronic acid, biocompatible salts thereof, copolymers thereof and intermolecular complexes thereof.
  • biocompatible intermolecular polymer complex is a complex of:
  • an anionic component comprising a linear or branched polysaccharide chain containing glucuronic acid
  • a non protein cationic component comprising a linear or branched natural, semi synthetic or synthetic oligomer or polymer.
  • the cationic component contains nitrogen that either carries a positive charge or the positive charge is induced by contact with the polysaccharidic anionic component.
  • the cationic component is selected from derivatives of acrylamide, methacrylamide and copolymers thereof.
  • the cationic component may be a cationised natural polysaccharide.
  • the polysaccharide is a starch, cellulose or gum.
  • the gum is guargumhydroxypropyltriammonium chloride.
  • the cationic component is a synthetic or semi-synthetic polyamino acid.
  • the cationic component is polylysin, polyarginin, or ⁇ , ⁇ -poly-[N-(2 hydroxyethyl)-DL-aspartamide].
  • the cationic component is a synthetic anti-fibrinolytic.
  • the anti-fibrinolytic is a hexadimethrindibromide (polybren).
  • the cationic component is a natural or semi-synthetic peptide.
  • the peptide is a protamine, gelatine, fibrinopeptide, or derivatives thereof.
  • the cationic component is an aminoglucane or derivatives thereof.
  • aminoglucane is fractionated chitin or its de-acetylated derivative chitosan.
  • the aminoglucane may be of microbial origin or is isolated from the shells of arthropods such as crabs.
  • the anionic component is polyanhydroglucuronic acid and/or bicompatible salts and/or copolymers thereof.
  • the polyanhydroglucuronic acid and salts thereof contain in their polymeric chain from 8 to 30 percent by weight of carboxyl groups, at least 80 per cent by weight of these groups being of the uronic type, at most 5 percent by weight of carbonyl groups, and at most 0.5 percent by weight of bound nitrogen.
  • the polyanhydroglucuronic acid and salts thereof contain in their polymeric chain at most 0.2 percent by weight of bound nitrogen.
  • the molecular mass of the polymeric chain of the anionic component is from 1 ⁇ 10 3 to 3 ⁇ 10 5 Daltons.
  • the molecular mass of the polymeric chain of the anionic component ranges from 5 ⁇ 10 3 to 1.5 ⁇ 10 5 Daltons.
  • the content of carboxyl groups is in the range of from 12 to 26 percent by weight, at least 95 percent of these groups being of the uronic type.
  • the anionic component contains at most 1 percent by weight of carbonyl groups.
  • the carbonyl groups are intra- and intermolecular 2,6 and 3,6 hemiacetals, 2,4- hemialdals and C2-C3 aldehydes.
  • the cationic component is gelatine.
  • the cationic component is chitosan.
  • the composition may include at least one biocompatible biologically active substance.
  • composition may alternatively or additionally include at least one biologically acceptable adjuvant.
  • composition may alternatively or additionally include at least one pharmaceutically active adjuvant.
  • the adjuvant is an anti-ulcer agent.
  • the adjuvant may be a H 2 -antagonist such as cimetidine.
  • the adjuvant is a combination of an antibiotic which is active against Helicobacter pylori and a H 2 -antagonist.
  • the composition may include bismuth salt.
  • composition may be in a form for oral administration such as a tablet, pellet, capsule, granule, or microsphere.
  • H 2 O 2 anal.grade 30% (Lachema, a.s. Neratovice)
  • N-HANCE 3000 guargumhydroxypropyltriammoniumchloride
  • mixer bottom stirring, 150 1 (duplicator), stainless steel EXTRA S
  • turbostirrer ULTRA TURAX (Janke-Kunkel)
  • N-HANCE 3000 were placed into and 5 1 beaker and 3 1 of demineralised water 2 ⁇ S were added. Contents of the beaker were intensely stirred for 30 minutes. The pH value was adjusted to less than 4.5 by addition of an acetic acid solution leading to a viscosity rise.
  • 60 1 of demineralised water 2 ⁇ S were introduced into a mixer. Then 3 kg of CaCl 2 .6H 2 O anal.grade were added and the contents heated up to a temperature of 50° C. under stirring. On dissolution of the calcium chloride the stiring was interrupted and 2.7 kg of the raw oxidised cotton wool were introduced. The mixer was closed and the contents were agitated for 120 seconds.
  • the pH value of the contents was adjusted by addition of a 20% solution of Na 2 CO 3 to 6-6.5 and 13 kg of H 2 O 2 30% were introduced.
  • the fibre suspension was slowly agitated for 10 minutes.
  • the pH value was readjusted to 4.5-5.0 and the prepared viscous solution of N-HANCE 3000 was introduced.
  • the contents of the mixer were stirred intensely for 30 seconds.
  • 60 1 of synthetic rectified ethanol conc. 98% were introduced into the mixer.
  • the contents of the mixer were transferred onto a vibrating screen, and the supernatant. Liquid was filtered off.
  • the filtration cake was redispersed in the mixer in 60 1 of a mixture of 18 1 of synthetic rectified ethanol conc. 98% and 42 1 of demineralised water 2 ⁇ S.
  • the fibre suspension was filtered again on the vibrating screen.
  • the isolated material thus prepared may further serve to prepare final products of the nonwoven type via a wet or dry process.
  • turbostirrer ULTRA TURAX (Janke-Kunkel)
  • the product can be used, for instance, for microembolisation, for preparation of haemostatic dusting powders, for manufacture of polymer drugs, e.g. based on cytostatics, or for preparation of spheric particles for macroembolisation.
  • turbostirrer ULTRA TURAX (Janke-Kunkel)
  • the temperature was decreased to 25-30° C. and the pH of the system was checked and adjusted to a value of 6.0-6.5. Subsequently, 626 ml of synthetic rectified ethanol conc. 98% were added gradually under intense stirring.
  • the suspension of IMC thus formed was isolated using a laboratory centrifuge. The supernatant liquid was filtered away and the cake was redispersed into 250 ml of 50% ethanol. The system was centrifuged again and after the separation of the supematant liquid, the IMC was redispersed into 250 ml of synthetic rectified ethanol conc. 98% and let to stay for 4 hours.
  • the product can be used, for instance, for microembolisation, for preparation of haemostatic dusting powders, for manufacture of polymer drugs, e.g. based on cytostatics, or for preparation of spheric particles for macroembolisation.
  • turbostirrer ULTRA TURAX (Janke-Kunkel)
  • the product can be used, for instance, for microembolisation, for preparation of haemostatic dusting powders, for manufacture of polymer drugs, e.g. based on cytostatics, or for preparation of spheric particles for macroembolisation.
  • turbostirrer ULTRA TURAX (Janke-Kunkel)
  • the supernatant liquid was filtered away and the cake was redispersed into, subsequently, 800 ml of 60% ethanol and 250 ml of 98% ethanol, wherein it was let to stay for a minimum of 10 hours.
  • the system was centrfuged again and the product was dried at 40° C. in a rotary vacuum dryer or a hot-air dryer. A white to slightly yellowish powder was obtained and further desagglomerated on an Alpine pin mill.
  • the product serves for the preparation of a mucoregulatory drug with a prolonged action.
  • the supernatant liquid was filtered away and the cake was redispersed into 250 ml of 50% ethanol.
  • the system was centrifuged again and after the separation of the supernatant liquid, the IMC was redispersed into 250 ml of synthetic rectified ethanol conc. 98% and let to stay for 4 hours. It was then centrifuged again, redispersed into 99.9% isopropanol, and let to stay for a rninimum of 10 hours at 20° C.
  • the gel formed was centrifuged again and the product was dried in a rotary vacuum dryer or a hot-air dryer.
  • the product can be used, for instance, for the manufacture of a dusting powder or a powder spray for the treatment of infected wounds.
  • N-HANCE 3000 guargumhydroxypropyltriammoniumchloride
  • rotary air pump rotor diameter 150 mm
  • turbostirrer ULTRA TURAX (Janke-Kunkel)
  • N-HANCE 3000 were placed into and 5 1 beaker and 3 1 of demineralised water 2 ⁇ S were added. Contents of the beaker were intensely stirred for 30 minutes. The pH value was adjusted to less than 4.5 by addition of an acetic acid solution leading to a viscosity rise.
  • the contents of the mixer were stirred intensely for 30 seconds. A solution of 35 g of chlorhexidine digluconate in 350 ml of demineralised water 2 ⁇ S was then introduced slowly within 10 minutes. Within another 10 minutes, a solution of polybren containing 120 g of polybrenu in 1000 ml of demineralised water 2 ⁇ S was added. Subsequently 60 1 of synthetic rectified ethanol conc. 98% were introduced into the mixer. After another 15 seconds from adding the ethanol, the contents of the mixer were transferred onto a vibrating screen, and the supernatant. Liquid was filtered off. The filtration cake was redispersed in the mixer in 60 1 of a mixture of 18 1 of synthetic rectified ethanol conc. 98% and 42 1 of demineralised water 2 ⁇ S. The fibre suspension was filtered again on the vibrating screen.
  • the isolated material thus prepared may further serve to prepare, via a wet or dry process, final products of the nonwoven type having an enhanced haemostatic activity and a bactericidal effect.
  • turbostirrer ULTRA TURAX (Janke-Kunkel)
  • the flask contents were then intensely stirred for another 10 minutes, and the pH of the system was adjusted, by addition of NaOH, to a value of 7.0.
  • a solution of clarithromycin 44 g of clarithromycin in 456 ml of redistilled H 2 O
  • the pH of the system was adjusted to a value of 7.0-7.5.
  • Stirring was interrupted, the flask contents were transferred into a dialysing bag and dialysed against water for 48 hours. Subsequently the product was isolated by centrifugation, lyophilised, and disintegrated on the laboratory pin mill ALPINE.
  • the product can be used, for instance, to prepare tablets or granules efficient against Helicobacter pylori occurring in the gastrointestinal tract.
  • turbostirrer ULTRA TURAX (Janke-Kunkel)
  • the system was centrifuged again and after the separation of the supernatant liquid, the IMC was redispersed into 250 ml of synthetic rectified ethanol conc. 98% and let to stay for a minimum of 4 hours. It was then centrifuged again, redispersed into 99.9% isopropanol, and let to stay for a minimum of 10 hours at 20° C.
  • the suspension formed was then centrifuged again and the product was dried in a rotary vacuum dryer or a hot-air dryer.
  • the product can be used, for instance, to prepare dusting powders for wound treatnent or tablets for treatment of gastrointestinal tract malfunctions.
  • turbostirrer ULTRA TURAX (Janke-Kunkel)
  • the supernatant liquid was filtered away and the cake was redispersed into 250 ml of 50% ethanol.
  • the system was centrifuged again and after the separation of the supernatant liquid, the IMC was redispersed into 250 ml of synthetic rectified ethanol conc. 98% and let to stay for 4 hours. It was then centrifuged again, redispersed into 99.9% isopropanol, and let to stay for a minimum of 10 hours at 20° C.
  • the gel formed was centrifuged again and the product was dried in a rotary vacuum dryer or a hot-air dryer.
  • the product can be used, for instance, to manufacture tablets or granulates for the treatment of the gastrointestinal tract or other non-malignant ulcerations.
  • turbostirrer ULTRA TURAX (Janke-Kunkel)
  • the IMC-MDOC complex as prepared in Example 2 above was redispersed into redistilled water in a sulphonation flask using a turbostirrer. A solution of Bestatin in methanol was then added to the flask in an amount sufficient to yield a 10% b/w concentration of Bestatin in the resulting Bestatin-gelatine-MDOC complex. After thorough homogenisation, the suspension formed was isolated by centrifugation. The supernatant liquid ws filtered away and the filtration cake was redispersed into concentrated methanol again, centrifuged, redispersed in diethylether, and after being allowed to stay for 1 hour, it was dried in a hot-air dryer.
  • the product a microdispersed form of a Bestatin-gelatine-MDOC complex, can be used, for instance, to prepare microembolisation agents used in regional chemotherapy of malignant tumours or flat dressing structures for wound treatment.
  • MDOC Microdispersed Oxidised cellulose.
  • MDOC Ca/Na salt of PAGA
  • particle size 0.1-2.0 ⁇ m, specific surface area 86 m 2 /g, COOH group content 22.2% b/w, Ca content 4.2% b/w, Na content 3.8% b/w
  • the tablets prepared were smooth and cohering and had a weight of 0.5 g. Disintegration rate of the tablets in a saline F1/1 was 15 minutes at 20 C., and 8 minutes at 37° C.
  • the tablets prepared were smooth and well cohering and had a weight of 0.5 g. Disintegration rate of the tablets in a saline F1/1 was 17 minutes at 20° C., and 8 minutes at 37° C.
  • MDOC particle size 0.1-2.0 ⁇ m, specific surface area 86m 2 ,
  • the tablets prepared were smooth and cohering and had a weight of 0.5 g. Disintegration rate of the tablets in a saline F1/1 was 12 minutes at 20° C,, and 5 minutes at 37° C.
  • MDOC suppresses formation of the stomach acidity, adjust the pH value of the environment, and protects the mucous membranes by forming a gel layer.
  • MDOC particle size 0.1-2.0 ⁇ m, specific surface area 86m 2 , COOH group content 22.2% b/w, Ca content 4.2% b/w, Na content 3.8% b/w
  • the tablets prepared were smooth and well cohering and had a weight of 1.0 g. Disintegration rate of the tablets in a saline F1/1 was 8 minutes at 20° C., and 6 minutes at 37° C.
  • MDOC particle size 0.1-2.0 gm, specific surface area 86 m 2 g,
  • mixer bottom agitated, vessel size 1000 ml, 8000 rpm, equipped with a nozzle for inlet of the granulation medium counter-flow drier BINDER
  • the granules can be used in the treatment of gastric ulcers.
  • MDOC suppresses formation of the stomach acidity, adjust the pH value of the environment, and protects the mucous membranes by forming a gel layer.
  • BiO + acts as a mild astringens. Clarithromycin depresses the growth of Helicobacter pylori beyond pathologic limits.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Dental Preparations (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
  • Laminated Bodies (AREA)
US09/764,347 1998-07-21 2001-01-19 Anti-ulcer composition Abandoned US20010012837A1 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
IE980594 1998-07-21
IE980596 1998-07-21
IES980594 1998-07-21
IE980599 1998-07-21
IE980598 1998-07-21
IE980597 1998-07-21
IE980595 1998-07-21
PCT/IE1999/000068 WO2000004891A2 (en) 1998-07-21 1999-07-21 Anti-ulcer composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/IE1999/000068 Continuation WO2000004891A2 (en) 1998-07-21 1999-07-21 Anti-ulcer composition

Publications (1)

Publication Number Publication Date
US20010012837A1 true US20010012837A1 (en) 2001-08-09

Family

ID=27547368

Family Applications (6)

Application Number Title Priority Date Filing Date
US09/764,347 Abandoned US20010012837A1 (en) 1998-07-21 2001-01-19 Anti-ulcer composition
US09/764,346 Expired - Lifetime US6596791B2 (en) 1998-07-21 2001-01-19 Polymer complexes of glucuronoglucanes
US09/764,348 Expired - Fee Related US6743775B2 (en) 1998-07-21 2001-01-19 Slow release formulations comprising anionic polysaccharide
US09/764,340 Expired - Lifetime US6706695B2 (en) 1998-07-21 2001-01-19 Antilipemic formulation
US10/463,875 Abandoned US20040106730A1 (en) 1998-07-21 2003-06-18 Polymer complexes of glucuronoglucanes
US11/298,887 Abandoned US20060275251A1 (en) 1998-07-21 2005-12-12 Polymer complexes of glucuronoglucanes

Family Applications After (5)

Application Number Title Priority Date Filing Date
US09/764,346 Expired - Lifetime US6596791B2 (en) 1998-07-21 2001-01-19 Polymer complexes of glucuronoglucanes
US09/764,348 Expired - Fee Related US6743775B2 (en) 1998-07-21 2001-01-19 Slow release formulations comprising anionic polysaccharide
US09/764,340 Expired - Lifetime US6706695B2 (en) 1998-07-21 2001-01-19 Antilipemic formulation
US10/463,875 Abandoned US20040106730A1 (en) 1998-07-21 2003-06-18 Polymer complexes of glucuronoglucanes
US11/298,887 Abandoned US20060275251A1 (en) 1998-07-21 2005-12-12 Polymer complexes of glucuronoglucanes

Country Status (15)

Country Link
US (6) US20010012837A1 (cs)
EP (4) EP1098640A1 (cs)
JP (4) JP2002521392A (cs)
CN (1) CN1309666B (cs)
AT (1) ATE259830T1 (cs)
AU (8) AU5061899A (cs)
CA (1) CA2338141C (cs)
CZ (1) CZ301410B6 (cs)
DE (1) DE69914928T2 (cs)
ES (1) ES2216543T3 (cs)
GB (1) GB2374075B (cs)
HK (1) HK1038757A1 (cs)
IE (7) IE990616A1 (cs)
IL (1) IL140992A0 (cs)
WO (8) WO2000004891A2 (cs)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180850A1 (en) * 2001-06-29 2004-09-16 Jari Natunen Methods and compositions for treatment of gastric diseases

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521392A (ja) * 1998-07-21 2002-07-16 アルペンストック・ホールディングス・リミテッド グルクロノグルカンのポリマーコンプレックス
DE10133546A1 (de) * 2001-07-11 2003-03-06 Petra Bastian Mischkomplexe zur Maskierung bitter schmeckender Substanzen
EP1423435A1 (de) * 2001-09-04 2004-06-02 Heppe GmbH Biotechnologische Systeme und Materialien Werkstoffe aus modifizierten polysacchariden und verfahren zu ihrer herstellung
WO2003068245A1 (en) * 2002-02-14 2003-08-21 Alpenstock Holdings Limited Use of polyanhydroglucuronic acid comprising microdispersed oxidised cellulose as immunomodulator
US20040153614A1 (en) * 2003-02-05 2004-08-05 Haim Bitner Tape storage emulation for open systems environments
JP2005220068A (ja) * 2004-02-05 2005-08-18 Toppan Printing Co Ltd 経口物用コーティング剤
AU2005217966B2 (en) * 2004-02-20 2008-05-22 Checkpoint Systems, Inc. System and method for authenticated detachment of product tags
US6998397B2 (en) * 2004-07-23 2006-02-14 Drebsk Comptech, Inc. Method for decreasing cholesterol level in blood
US7355235B2 (en) * 2004-12-22 2008-04-08 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor device and method for high-k gate dielectrics
DE602005019627D1 (de) 2005-03-22 2010-04-08 Ericsson Telefon Ab L M Verfahren und anordnung für auf einer dienstausführungsplattform ablaufende dienste
WO2007036920A2 (en) * 2005-09-28 2007-04-05 Alltracel Development Services Limited Therapeutic use of polyanhydroglucronic acid
US20070248653A1 (en) * 2006-04-20 2007-10-25 Cochrum Kent C Hemostatic compositions and methods for controlling bleeding
WO2008010199A2 (en) * 2006-07-18 2008-01-24 Nanopeutics S.R.O. A nanofibre product
US8932560B2 (en) 2007-09-04 2015-01-13 University of Maryland, College Parke Advanced functional biocompatible polymeric matrix used as a hemostatic agent and system for damaged tissues and cells
CN101932719B (zh) * 2007-04-26 2014-04-02 株式会社林原 支链α-葡聚糖及生成其的α-葡糖基转移酶和它们的制造方法以及用途
ATE520811T1 (de) * 2007-06-19 2011-09-15 Procter & Gamble Vliesnetze aus behandelten fasern
WO2011044421A1 (en) 2009-10-08 2011-04-14 C. R. Bard, Inc. Spacers for use with an ultrasound probe
CA2780898A1 (en) 2009-11-13 2011-05-19 University Of Maryland, College Park Advanced functional biocompatible foam used as a hemostatic agent for compressible and non-compressible acute wounds
WO2011119232A2 (en) 2010-03-23 2011-09-29 Oewaves, Inc. Optical gyroscope sensors based on optical whispering gallery mode resonators
US9309435B2 (en) 2010-03-29 2016-04-12 The Clorox Company Precursor polyelectrolyte complexes compositions comprising oxidants
US9474269B2 (en) * 2010-03-29 2016-10-25 The Clorox Company Aqueous compositions comprising associative polyelectrolyte complexes (PEC)
US20110236582A1 (en) 2010-03-29 2011-09-29 Scheuing David R Polyelectrolyte Complexes
WO2011151810A1 (en) 2010-06-03 2011-12-08 Hemcon Medical Technologies (Ip) Limited A surgical gel system
AU2011289513B2 (en) 2010-08-09 2014-05-29 C.R. Bard, Inc. Support and cover structures for an ultrasound probe head
WO2012060110A1 (ja) * 2010-11-05 2012-05-10 江崎グリコ株式会社 アミノ糖含有グルカン、その製造法および利用
AU2012229476B2 (en) 2011-03-01 2016-02-25 The Procter & Gamble Company Porous disintegratable solid substrate for personal health care applications
USD724745S1 (en) 2011-08-09 2015-03-17 C. R. Bard, Inc. Cap for an ultrasound probe
USD699359S1 (en) 2011-08-09 2014-02-11 C. R. Bard, Inc. Ultrasound probe head
US9211107B2 (en) 2011-11-07 2015-12-15 C. R. Bard, Inc. Ruggedized ultrasound hydrogel insert
WO2013188833A2 (en) 2012-06-15 2013-12-19 C.R. Bard, Inc. Apparatus and methods for detection of a removable cap on an ultrasound probe
US9616088B2 (en) 2013-03-13 2017-04-11 Gel-E, Inc. Advanced functional biocompatible polymer putty used as a hemostatic agent for treating damaged tissue and cells
CN103204957B (zh) * 2013-04-27 2015-11-11 武汉大学 一种温敏性甲壳素及其制备方法
CN103224575A (zh) * 2013-04-27 2013-07-31 武汉大学 一种丙烯酰胺甲壳素及其制备方法
WO2015042104A1 (en) * 2013-09-17 2015-03-26 Biolife, L.L.C. Improved adaptive devices and methods for endoscopic wound closures
CA2931547A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
US8975220B1 (en) 2014-08-11 2015-03-10 The Clorox Company Hypohalite compositions comprising a cationic polymer
RU2578035C1 (ru) * 2014-11-05 2016-03-20 Общество с ограниченной ответственностью Малое научно-производственное предприятие "Старт-Фарм" Противохеликобактерное бактерицидное средство и способ его получения
CN104839198B (zh) * 2015-03-20 2017-05-10 山西省农业科学院植物保护研究所 一种用于防治桃小食心虫的温敏型农药缓释剂
CZ307155B6 (cs) * 2016-12-16 2018-02-07 Synthesia, A. S. Supramolekulární komplex oxycelulózové matrice s antracyklinovým cytostatikem s postupným uvolňováním antracyklinového cytostatika a jeho použití
RU194279U1 (ru) * 2019-07-16 2019-12-05 Владимир Владимирович Гришин Гранулы для остановки кровотечений различной степени тяжести
EP4306138A4 (en) * 2021-03-12 2025-03-12 Artisan Lab Co., Ltd. HEMOSTATIC MATERIAL

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB709684A (en) * 1951-09-21 1954-06-02 Nyma Kunstzijdespinnerij Nv Improvements in or relating to the oxidation of cellulose
FR2167219A1 (en) * 1972-01-10 1973-08-24 Faure Laboratoires Polyuronic mucilage from cassia absus - for treatment of peptic ulcer and gastric mucosal disorders
GB1457885A (en) 1973-03-29 1976-12-08 Gallaher Ltd Oxidation of cellulose
JPS5114179A (cs) * 1974-07-26 1976-02-04 Fuji Photo Film Co Ltd
JPS54148090A (en) * 1978-05-11 1979-11-19 Ajinomoto Co Inc Peroral cholesterol-depressant
CS235108B1 (cs) * 1981-06-24 1985-05-15 Ivan Blazicek Hemostatická hmota
JPS59500217A (ja) * 1982-02-22 1984-02-16 ベロルススキ−　ナウチノ−　イスレドワ−チエルスキ−　サニタルノ−　ギギエニチエスキ−　インスチツ−ト 抗ニコチン効果を有する製剤およびその製造法
JPS5938204A (ja) * 1982-08-27 1984-03-02 Showa Sangyo Kk 多糖類及びその製法並びにそれを有効成分とする降コレステロ−ル剤
CS235470B1 (cs) * 1982-10-19 1985-05-15 Maxmilian Mozisek Hemostatické hemoroidálnf čípk
JPS59163323A (ja) * 1983-03-08 1984-09-14 Showa Sangyo Kk 動脈硬化性疾患防止剤
CS242920B1 (cs) * 1984-02-16 1986-05-15 Jiri Briestensky Sorbent na bázi oxidované celulózy a způsob jeho výroby
JPS6164701A (ja) * 1984-09-06 1986-04-03 Meito Sangyo Kk カチオン化デキストラン誘導体とポリウロン酸の高分子電解質錯体及びその利用
DE3669876D1 (de) * 1985-05-13 1990-05-03 Kuraray Co 3,4-dihydrobenzopyranderivate.
JPS61293913A (ja) * 1985-06-21 1986-12-24 Kuraray Co Ltd 肝臓疾患治療剤
CS253042B1 (en) * 1985-09-25 1987-10-15 Maxmilian Mozisek Haemostatical material
JPS6396155A (ja) * 1986-10-13 1988-04-27 Kuraray Co Ltd 新規なテルペン化合物およびこれを含有する抗炎症剤
JPS646260A (en) * 1987-06-27 1989-01-10 Yamasa Shoyu Kk 6-iodoacyclouridine derivative
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
JPH02221224A (ja) * 1989-02-22 1990-09-04 Tatsuaki Yamaguchi 尿素吸着剤の製造方法
CS276813B6 (cs) * 1990-05-10 1992-08-12 Leciva Přípravek pro léčení hemoroidů
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5166137A (en) 1991-03-27 1992-11-24 Nobipols Forskningsstiftelse Guluronic acid polymers and use of same for inhibition of cytokine production
IT1263755B (it) * 1991-09-16 1996-08-29 Fidia Spa Uso di esteri della colina con polisaccaridi acidi come agenti antiulcera e gastroprotettivi
IT1254704B (it) * 1991-12-18 1995-10-09 Mini Ricerca Scient Tecnolog Tessuto non tessuto essenzialmente costituito da derivati dell'acido ialuronico
JPH0662425B2 (ja) * 1992-12-02 1994-08-17 生化学工業株式会社 ヒアルロン酸含有血中脂質低下剤
AU8129894A (en) * 1993-11-01 1995-05-23 Alpha-Beta Technology, Inc. Derivatized polysaccharide bile acid sequestrant for reducing cholesterol
CZ288792B6 (cs) 1993-12-23 2001-09-12 Johnson & Johnson Medical, Inc. Bioabsorbovatelný chirurgický hemostat a způsob jeho výroby
JPH07188038A (ja) * 1993-12-28 1995-07-25 Kao Corp 高脂血症治療剤
JPH07309766A (ja) * 1994-05-20 1995-11-28 Sekisui Chem Co Ltd コレステロール低下剤
BR9612051A (pt) * 1995-12-18 1999-02-09 Degussa Implante médico
US5593682A (en) * 1995-12-29 1997-01-14 Eastman Chemical Company Skin treating composition
GB2314842B (en) * 1996-06-28 2001-01-17 Johnson & Johnson Medical Collagen-oxidized regenerated cellulose complexes
ATE209661T1 (de) * 1997-01-30 2001-12-15 Alpenstock Holdings Ltd Cellulosederivate
JP4132125B2 (ja) * 1997-04-16 2008-08-13 タカラバイオ株式会社 ヘリコバクター・ピロリ接着阻害剤
JP2002521392A (ja) * 1998-07-21 2002-07-16 アルペンストック・ホールディングス・リミテッド グルクロノグルカンのポリマーコンプレックス

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180850A1 (en) * 2001-06-29 2004-09-16 Jari Natunen Methods and compositions for treatment of gastric diseases

Also Published As

Publication number Publication date
DE69914928T2 (de) 2004-12-16
AU5061899A (en) 2000-02-14
EP1115747A1 (en) 2001-07-18
GB2374075A (en) 2002-10-09
AU5061799A (en) 2000-02-14
US6596791B2 (en) 2003-07-22
IE990617A1 (en) 2000-05-03
CA2338141A1 (en) 2000-02-03
US20040106730A1 (en) 2004-06-03
IE990616A1 (en) 2000-05-03
US20010003742A1 (en) 2001-06-14
WO2000005269A1 (en) 2000-02-03
EP1115747B1 (en) 2004-02-18
EP1098640A1 (en) 2001-05-16
IE990614A1 (en) 2000-05-03
GB0030730D0 (en) 2001-01-31
US6706695B2 (en) 2004-03-16
IE990638A1 (en) 2000-05-03
WO2000004925A1 (en) 2000-02-03
CA2338141C (en) 2009-10-27
WO2000004877A1 (en) 2000-02-03
CN1309666B (zh) 2011-07-27
IE990618A1 (en) 2000-05-03
AU5062099A (en) 2000-02-14
AU5062199A (en) 2000-02-14
AU5062399A (en) 2000-02-14
WO2000004937A1 (en) 2000-02-03
WO2000004891A2 (en) 2000-02-03
DE69914928D1 (de) 2004-03-25
EP1098663A1 (en) 2001-05-16
WO2000004939A1 (en) 2000-02-03
US6743775B2 (en) 2004-06-01
WO2000004891A3 (en) 2001-04-12
AU5062299A (en) 2000-02-14
EP1098654A1 (en) 2001-05-16
ES2216543T3 (es) 2004-10-16
JP2002521347A (ja) 2002-07-16
WO2000004907A1 (en) 2000-02-03
JP2002521338A (ja) 2002-07-16
JP2002521327A (ja) 2002-07-16
AU758383B2 (en) 2003-03-20
CN1309666A (zh) 2001-08-22
WO2000004882A1 (en) 2000-02-03
US20060275251A1 (en) 2006-12-07
US20010006957A1 (en) 2001-07-05
GB2374075B (en) 2003-09-10
IE990615A1 (en) 2000-05-03
ATE259830T1 (de) 2004-03-15
JP2002521392A (ja) 2002-07-16
AU5062499A (en) 2000-02-14
CZ301410B6 (cs) 2010-02-17
AU5061999A (en) 2000-02-14
IE990611A1 (en) 2000-05-03
IE990613A1 (en) 2000-05-03
CZ2001230A3 (en) 2001-06-13
HK1038757A1 (zh) 2002-03-28
IL140992A0 (en) 2002-02-10
US20030040487A1 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
US20010012837A1 (en) Anti-ulcer composition
AU712464B2 (en) Improvements in or relating to organic compositions
US20210267903A1 (en) Gastro-Retentive Sustained-Release Oral Dosage Form of a Bile Acid Sequestrant
WO1997019699A1 (fr) Composition de medicament
Setia et al. Applications of gum karaya in drug delivery systems: a review on recent research
EP0761227A1 (en) Solid antacid and process for producing the same
CA3155818A1 (en) Delayed release composition comprising enteric coated drug loaded in psyllium husk matrix
IE83675B1 (en) Polymer complexes with polysaccharide comprising glucuronic acid residues
HK1214529B (en) Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant
ZA200100514B (en) Polymer complexes of glucuronoglucanes.

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALPENSTOCK HOLDINGS LIMITED, IRELAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SANTAR, IVAN;KISS, FRANTISEK;BRIESTENSKY, JIRI;REEL/FRAME:011479/0685

Effective date: 20010110

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION